Analyst Conference Summaries

Biotechnology Investor Aids

Protalix BioTherapeutics
PLX

conference date: May 14, 2021 @ 5:30 AM Pacific Time

Protalix Should Go Higher If FDA Approves Fabry Disease Therapy [June 4, 2020 @ Seeking Alpha]

FDA Okays Phase 3 Study of PRX-102 for Fabry Disease [November 16, 2015]

Protalix Positive Preclinical Results for NASH [October 5, 2015]
Protalix Positive Interim Phase I/II Data for PRX-102 [Jan. 8, 2015]

2021
Protalix
Q1 2021
     
May 14, 2021      
2020
Protalix
Q1 2020
Protalix
Q2 2020
Protalix
Q3 2020
Protalix
Q4 2020
June 1, 2020 Aug. 10, 2020 Oct. 29, 2020 March 30, 2021
2019
Protalix
Q1 2019
Protalix
Q2 2019
Protalix
Q3 2019
Protalix
Q4 2019
May 6, 2019 August 8, 2019 Nov. 7, 2019 Mar. 12, 2020
2018
Protalix
Q4 2018
May 9, 2018
Aug. 9, 2018
Nov. 7, 2018
Mar. 14, 2019
2017
May 10, 2017
August 9, 2017
Nov. 8, 2017
March 6, 2018
2016
05/09/2016
08/08/2016
11/09/2016
03/16/2017
2015
 05/07/2015
08/10/2015 
 11/09/2015
 03/08/2016

Protalix BioTherapeutics (PLX) is a biotechnology company making proprietary recombinant therapeutic proteins with its ProCellEx plant cell based protein expression system.

Protalix does not currently hold quarterly conference calls for analysts. It is based in Israel, but registered in Florida and files with the SEC.

Protalix BioTherapeutics web site
Protalix investor relations page


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 DRNA
 EPZM
 GILD
 GLYC
 ILMN
 INCY
 INO
 IONS
 ISRG
 MCHP
 REGN
 RNA
 SAGE
 SGEN
 SYRS
 VBLT
 VSTM
 XLNX
 XLRN

 
 
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is financial journalism, not advice. These notes may also be the basis for my Seeking Alpha articles.

Copyright 2021 William P. Meyers